Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Casodex’ (bicalutamide) 150mg a cost effective treatment for the management of locally advanced prostate cancer[1]

18.01.2005


New health economic data published in the European Journal of Hospital Pharmacy outline the cost benefits of the non-steroidal anti-androgen bicalutamide 150mg for the treatment of locally advanced prostate cancer. By delaying disease progression in patients with locally advanced prostate cancer, bicalutamide 150mg reduces the additional healthcare costs associated with treating advanced disease.



The paper by Dr Heather Payne, Middlesex Hospital UCL, London states that bicalutamide 150mg impacts less on healthcare budgets compared to other types of cancer treatments.1* An analysis of the cost-effectiveness of bicalutamide 150mg based on the first analysis of the Early Prostate Cancer (EPC) Trial, shows that its estimated cost-effectiveness per quality-adjusted life year (£10,067) falls well below the commonly used threshold for cost-effectiveness (£29,212) and compares well with the cost-utilities of other approaches used in oncology.2,3

The cost of bicalutamide 150mg (administered for three years) plus radical prostatectomy or radiotherapy for locally advanced prostate cancer is also significantly lower compared to the cost of other oncology treatments.2,3


Progression of locally advanced prostate cancer can result in costly complications such as bone metastases and serious skeletal complications.4

In addition, Dr Payne highlights in her paper, that bicalutamide 150mg gives a significant improvement in progression-free survival in patients with locally advanced disease, reducing the risk of objective disease progression by 42% in radiotherapy patients, 47% in watchful waiting patients, and 29% in radical prostatectomy patients.5

As well as being as effective as castration in prolonging survival in non-metastatic prostate cancer6, bicalutamide 150mg has significant quality-of-life benefits, with improvements over castration-based therapies in terms of maintaining bone mineral density, physical capacity and sexual activity.6,7 A recent study of the risk of osteoporosis in men with non-metastatic prostate cancer revealed that those who were treated with bicalutamide 150mg maintained bone mineral density (BMD), whilst those who received castration were associated with a progressive loss of BMD, which can result in costly complications such as increased risk of fractures.7

Dr Payne concludes: “Bicalutamide 150mg is a cost-effective therapy for patients with locally advanced prostate cancer, delaying disease progression, and offers a valuable alternative to castration in this setting”.

Bicalutamide 150mg is indicated in the UK in patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.8

*Data is based on UK NHS costs and may vary in other countries

References:

1. Payne, H. The value of delaying disease progression with bicalutamide (‘Casodex’) 150mg in locally advanced prostate cancer. European Journal of Hospital Pharmacy. 2004.

2. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (CasodexTM) for adjuvant treatment of early prostate cancer. Value Health 2004; 7: 472-81.

3. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ.

Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-17.

4. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer,

metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226-32.

5. Wirth M et al. Bicalutamide (Casodex) 150mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years. J Urol. 2004; 172: 1865–1870.

6. Iversen P, Tyrell CJ, Kaisary AV et al Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J.Urol 2000; 164: 1579-1582.

7. Sieber PR, Keiller DL, Kahnoski RJ et al Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Urology 2004; 171: 2272-6.

8. AstraZeneca; Casodex (bicalutamide)150mg Summary of Product Characteristics.

Bea Shake | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>